Publications

 
 

Non-Hodgkin Lymphoma

Critical Reading

  1. Reduced Dose RT for Local Control in NHL

  2. FORT Trial

  3. RICOVER-60 NoRTh

Supplemental Reading

DLBCL

  1. DLBCL ACR Appropriateness Criteria 

  2. Re-examining the Role of RT for DLBCL in the Modern Era

  3. SWOG 8516: CHOP vs. Other Intensive Chemotherapy Regimens

  4. SWOG S8736 CHOP3 + RT vs. CHOP8

  5. LNH-98.5: CHOP vs R-CHOP 

  6. MInT: CHOP vs. R-CHOP

  7. IFRT vs INRT as Consolidation for DLBCL 

  8. LYSA trial: R-CHOP +/- RT

  9. Consolidative RT after R-CHOP: MDACC Experience

  10. Skeletal DLBCL 

  11. NCDB: Use of RT for DLBCL

  12. SEER: Use of RT for DLBCL

  13. PARMA: +/- ASCT for Relapsed NHL

  14. RT for Relapsed/Refractory DLBCL 

  15. DLBCL Subtypes by Gene Expression Profiling 

  16. Hans Algorithm: Classification of DLBCL Subtypes by Immunohistochemistry

  17. Reduction of the treated volume to INRT as part of CMT for early stage aggressive NHL

PMBCL

  1. NCI Phase 2 Trial: Dose-Adjusted R-EPOCH for PMBCL

  2. IELSG26: Response Assessment by PET in PMBCL

  3. Improved Survival with Combined Modality for PMBCL

Primary CNS Lymphoma

  1. IELSG32 Phase 2 Trial: Consolidative WBRT vs. ASCT

  2. R-MPV + reduced dose WBRT: MSKCC Experience

Follicular Lymphoma

  1. LymphoCare: Patterns of Care for FL in the USA

  2. TROG 99.03: IFRT +/- R-CVP for FL

  3. Salvage Treatment and Survival for Relapsed FL Following Primary RT: Collaborative ILROG Study

  4. Definitive RT for localized FL staged by 18F-FDG PET-CT: Collaborative ILROG Study

Marginal Zone Lymphoma

  1. Gastric MALT Treated with RT Alone: MSKCC Experience

  2. Orbital MALT treated with low-dose RT: Stanford Experience

  3. Long-term outcome of early-stage extranodal marginal zone lymphoma: MSKCC Experience

  4. Long-term outcome of early-stage extranodal marginal zone lymphoma after RT: MSKCC Experience

Mantle Cell Lymphoma

  1. Early-stage MCL: A Retrospective Analysis from ILROG

  2. RT as an Effective Modality for MCL

  3. 4Gy as an Effective Treatment of MCL

Cutaneous Lymphoma

  1. Efficacy of 12 Gy TSEB 

  2. RT for Low-grade Cutaneous B-cell Lymphoma